Teewinot Life Sciences Corporation Announces New Cannabis Genome Research Program

TAMPA, Fla., May 22, 2017 /PRNewswire/ — Teewinot Life Sciences Corporation (Teewinot), a global leader in the use of patent-protected biosynthetic processes for the manufacture of commercial quantities of pharmaceutical grade cannabinoids, cannabinoid prodrugs, and cannabinoid analogs, announced today that it has entered into an ambitious Cannabis genome research program in collaboration with Dr. Subha Madhavan, Director of the Innovation Center for Biomedical Informatics at the Georgetown University Medical Center and Seach Ltd., a leading Israeli Cannabis genetics company.

Currently, Teewinot can produce commercial quantities of at least 18 different naturally-occurring cannabinoids in pharmaceutically pure form using its proprietary CannSynthesis™ technology, including:  THCA, THC, THCVA, THCV, CBDA, CBD, CBDVA, CBDV, CBCA, CBC, CBCVA, CBCV, CBGA, CBG, CBGVA, CBGV, CBNA and CBLA.  Dr. Richard Peet, Teewinot’s Executive Vice President and co-inventor of the CannSynthesis™ technology stated, “We intend to unlock the Cannabis genome to unleash new methods

... read more at: http://www.prnewswire.com/news-releases/teewinot-life-sciences-corporation-announces-new-cannabis-genome-research-program-300460851.html

Leave a Reply

Your email address will not be published. Required fields are marked *